Macular Function During Anti-VEGF Treatment

Study of Macular Function During Anti-VEGF Treatment

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01023971

Acronym

MAFAT

Enrollment

Registered

2009-12-02

Start date

2009-01-31

Completion date

Unknown

Last updated

2009-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Macular Degeneration

Brief summary

The purpose of this study is to determine the changes in macular function during anti-VEGF treatment for neovascular age-related macular degeneration.

Detailed description

Macular function will be investigated using visual acuity, contrast sensitivity, mfERG and microperimetry.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Neovascular AMD in first or second eyes * angiographic signs of active subfoveal or juxtafoveal choroidal neovascularization (CNV) * BCVA ≥35 ETDRS letters

Exclusion criteria

* Spherical equivalent ≥ ± 6 D * Previous treatments for CNV in the studied eye

Design outcomes

Primary

Measure	Time frame
mfERG central ring amplitude density	12 months

Secondary

Measure	Time frame
Mean retinal sensitivity (dB) in three concentric rings (4°, 8° & 12°)	12 months
Choroidal blood flow (ChBFlow) at fovea and at optic nerve head	12 months

Countries

United Kingdom

Contacts

Primary ContactSimon P Harding, FRCOphth, MD

S.P.Harding@liverpool.ac.uk+44 0151 706

Backup ContactClaudio S Campa, MD, PhD

Claudio.Campa@rlbuht.nhs.uk+44 0151 706

Outcome results